4'-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)-[1,1'-biphenyl]-4-carbaldehyde, 97%, 250mg

beta-Glutamic Acid Hydrochloride>98.0%(T)(N)250mg

2-(9,9'-Spirobi[fluoren]-3-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane, 99%, 10g

2-Methyl-5-(trifluoromethoxy)aniline, 95.0%, 10g

3-Bromo-9-(2-ethylhexyl)-9H-carbazole>98.0%(GC)1g

3-Methoxybenzenethiol>98.0%(GC)25g

2-(3-((3-Fluorobenzyl)oxy)phenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane, 250mg

(4-(1-Morpholinoethyl)phenyl)boronic acid hydrochloride, 95+%, 1g

GC-Kapillarsäule ROTI®Cap-1701, L 60 m, Ø-Innen 0,32 mm, Filmd. 0,35 µm, 1 Stück

2-Amino-1-(1-methyl-1 H -imidazol-2-yl)-ethanoldihydrochloride, 95.0%, 250mg

(S)-2-(2-((tert-Butoxycarbonyl)amino)-3-(1-trityl-1H-imidazol-4-yl)propanamido)-2-methylpropanoic acid, 97%, 25g

1-(5-Chloro-2-hydroxy-3-methylphenyl)ethan-1-one, 97%, 100mg

4-(Tert-butyl)-3-fluoroaniline, 98%, 250mg